Nonalcoholic steatohepatitis (NASH) is a growing global health concern, with no FDA-approved treatments currently available. However, the push for effective NASH therapeutics is driving significant research and investment. Pharmaceutical companies are actively developing therapies targeting fibrosis, inflammation, and metabolic dysfunction, shaping the landscape of the NASH pipeline.

Leading Drug Candidates in Clinical Trials

Several promising therapies are progressing through different stages of development, each addressing key aspects of NASH:

✅ Itagliptin – A DPP-4 inhibitor that enhances insulin sensitivity and may help alleviate liver inflammation.
✅ Terlipressin (Terlipre) – Primarily used for hepatorenal syndrome, now being investigated for its potential to lower portal hypertension, a frequent NASH complication.
✅ PPAR Agonists (NASH PPARs) – These drugs help regulate lipid metabolism and inflammation, showing strong potential in clinical studies.
✅ MSDC-0602K (Cirius Therapeutics) – A mitochondrial modulator designed to improve insulin resistance and slow fibrosis progression.
✅ Belapectin (Galectin Therapeutics) – A galectin-3 inhibitor targeting liver fibrosis, sparking speculation about a Galectin Therapeutics buyout.

Conclusion

The search for innovative NASH therapeutics is driving rapid advancements within the NASH pipeline. As clinical trials progress and discussions about a Galectin Therapeutics buyout continue, the NASH treatment landscape is poised for significant change. These emerging therapies provide hope for millions affected by this progressive liver disease.

Latest reports offered by Delveinsight

ANCA Vasculitis Market | Familial Lipoprotein Lipase Deficiency Market | Focal Segmental Glomerulosclerosis Market | Herpes Labialis Market | Langerhans Cell Histiocytosis Market | Opioid-Related Disorders Market | Pancreatic Endocrine Tumor Market | Pelvic Organ Prolapse Market | Polymyalgia Rheumatica Market | Recurrent Herpes Labialis Market | Secondary Progressive Multiple Sclerosis Market | Spinocerebellar Ataxia Market | Surgical Bleeding Market | Tonic Clonic Seizure Market | Urology Ultrasounds Devices Market | Uveitis Market | Carbapenem-Resistant Enterobacteriaceae Infection Market | Glioblastoma Multiforme Market | Pediatric Brain Tumor Market | Rubella Market | Smoking Cessation and Nicotine Addiction Market | Wilms Tumor Market

Contact information

Kanishk

kkumar@delveinsight.com